om stock: Outset Medical Overview

OM (Outset Medical, Inc.)

Keyword note: This article uses the term "om stock" throughout to refer to the Nasdaq-listed equity for Outset Medical, Inc.

Introduction

om stock refers to the Nasdaq ticker OM, the publicly traded equity of Outset Medical, Inc., a U.S.-based medical-technology company best known for the Tablo Hemodialysis System. This guide explains what Outset Medical does, how its products and business model work, how to find official stock information, common investor considerations, and where to verify up-to-date market data. The goal is beginner-friendly clarity with links to authoritative sources and practical next steps — including how to view or trade om stock using mainstream broker services and how Bitget products can support your market activities.

As of Jan 27, 2026, according to Nasdaq and the company's investor relations updates, OM is listed and actively traded on Nasdaq under the ticker OM. For live market quotes and exact figures such as market capitalization and trading volume, consult Nasdaq, Yahoo Finance, Morningstar or major financial news providers and your brokerage platform.

Company overview

Outset Medical, Inc. designs, manufactures and markets dialysis therapy systems intended to simplify dialysis delivery in hospitals, clinics and home settings. The company's flagship offering is the Tablo Hemodialysis System, an integrated console-and-cartridge platform that combines water purification, on-demand dialysate production and electronic monitoring. Outset's product strategy centers on ease of use, mobility, reduced infrastructure needs and data connectivity to enable dialysis outside of traditional, infrastructure-heavy settings.

The company targets acute-care facilities (hospitals and dialysis clinics), and it has been expanding into home dialysis markets and related-service offerings. Outset aims to reduce the logistical burden of dialysis therapy, improve throughput in acute-care environments and increase patient access to dialysis where water quality or facility infrastructure are limiting factors.

History

• Founding and early development: Outset Medical was founded to address inefficiencies in dialysis delivery and to develop a more portable, integrated dialysis system. Early R&D focused on integrating water treatment, dialysate generation and user-friendly interfaces into a single platform.

• Product milestones: The Tablo Hemodialysis System reached clinical and regulatory milestones before commercial roll-out. Key milestones include clinical testing in acute-care environments, regulatory clearances in the U.S. and other jurisdictions, and commercial launches for hospital and clinic customers.

• IPO and listing: Outset Medical completed its initial public offering and listing on Nasdaq (ticker OM). As of Jan 27, 2026, company investor relations and Nasdaq pages show OM as an active listing. For the official IPO date and underwriting details, consult the company’s SEC filings and investor relations materials.

• Recent commercial and partnership activity: Over time, Outset secured partnerships, expanded its sales and service networks, and pursued software and data integrations (Tablo Data Ecosystem). The company has also advanced efforts to support home dialysis adoption through product updates and training programs.

Products and services

Outset’s portfolio centers on the Tablo Hemodialysis System and related consumables and software. Below are the major categories.

Tablo Hemodialysis System (hardware)

• Console and cartridge: The Tablo system uses a compact console plus disposable cartridges. The cartridge simplifies setup and reduces cross-contamination risk.

• Integrated water purification and on-demand dialysate: Tablo can purify water and produce dialysate on demand, reducing the need for complex facility-level water infrastructure.

• Usability: The console is designed for simplified setup and operation, with touchscreen controls and workflow guidance aimed at clinicians and trained caregivers.

Consumables and disposables

• Cartridges and single-use components: Ongoing revenue is generated by sales of disposable cartridges and other consumables required per treatment.

• Replacement parts and service contracts: Maintenance, warranty extensions and service agreements are additional revenue streams.

Tablo Data Ecosystem (software and connectivity)

• TabloHub and TabloDash: These cloud-enabled tools provide remote monitoring, fleet management, usage analytics and device status dashboards for clinical administrators.

• Patient and caregiver interfaces: MyTablo-type apps or portals often support patient engagement and home-use workflows.

Services

• Training, installation and support: On-site or remote training and installation services support clinical adoption and device uptime.

• Technical service and spare parts logistics: Field service teams and distribution partners ensure devices remain operational.

Business model and operations

Outset Medical's revenue model typically combines one-time hardware sales with recurring consumables and service revenue. The major components include:

• Hardware: Sales of the Tablo console contribute a capital-equipment revenue stream.

• Consumables: Repeat purchases of cartridges and disposables create recurring revenue tied to utilization (number of treatments performed).

• Software and data services: Subscription or service fees for TabloHub, data analytics, and fleet management may contribute incremental recurring revenue.

• Services: Training, installation, extended service agreements and field maintenance.

Target markets and go-to-market approach:

• Acute-care hospitals: Outset targets hospital intensive care units and dialysis centers where portability and simplified infrastructure reduce operational friction.

• Outpatient dialysis clinics: Facilities that benefit from reduced setup time and simplified water treatment.

• Home dialysis: Growing focus on enabling home hemodialysis with a simplified system and remote monitoring.

Manufacturing and distribution:

• Vertical model: Outset manufactures consoles and sources disposable cartridges; some production is internal while other components may be outsourced to contract manufacturers.

• Distribution and partners: The company uses direct sales teams, distributor agreements and partnerships for international markets and service coverage.

Financials

This section summarizes the types of financial metrics investors review for om stock and how to locate them. Because market figures and quarterly results change, always verify current numbers on official filings and recognized financial data providers.

• Revenue and growth: Outset reports revenue from device sales, consumables and services. Investors track trailing-12-month (TTM) revenue and quarter-over-quarter growth to assess adoption.

• Profitability: Historically, capital-intensive medical-device companies may show operating losses during growth phases due to R&D, sales expansion and manufacturing scale-up. Investors look at gross margin on consumables versus hardware and whether recurring consumable revenue is improving margins.

• Cash position and liquidity: Cash, cash equivalents and available credit lines are critical to fund operations and commercial expansion. Debt levels, if any, and maturities are relevant for financial risk.

• Operating metrics: Unit placements (number of Tablo consoles deployed), per-device utilization (treatments per device), and consumables sold per treatment are key operational metrics that translate into revenue visibility.

• Quarterly reporting cadence: Outset files quarterly (10-Q) and annual (10-K) reports with the U.S. SEC; those filings and the company’s investor relations releases include audited and unaudited financial statements as well as management discussion and analysis.

As of Jan 27, 2026, investors should consult the company’s latest 10-Q/10-K and earnings releases for the most recent revenue, operating loss/profit, cash position and debt disclosure. Reliable financial-data aggregators such as Yahoo Finance, Morningstar and CNBC also display summarized metrics and historical trends.

Stock information

This section explains how om stock is structured and where to find market data.

Ticker and exchange

• Ticker: OM
• Exchange: Nasdaq (U.S. equities market)

om stock is actively tracked across market-data providers including Nasdaq, Yahoo Finance, CNBC, Morningstar and broker platforms.

Share structure and market capitalization

• Shares outstanding and float: Share counts (basic and diluted) and public float are disclosed in SEC filings and investor presentations.

• Market capitalization: Market cap for om stock fluctuates with the share price; for a current figure, consult Nasdaq, Yahoo Finance or Morningstar.

Liquidity and trading volume

• Average daily trading volume and typical bid-ask spreads indicate liquidity. om stock liquidity is visible on exchange quote pages; investors use volume to gauge execution risk for large orders.

Price range and volatility

• 52-week high and low: Financial portals list the 52-week trading range for om stock; volatility can be higher around earnings, FDA/regulatory news and major partnerships.

Sources for live quotes

Common sources to view live or delayed market data for om stock include Nasdaq, Yahoo Finance, CNBC, Morningstar, and brokerage account quote pages. For execution, select your preferred brokerage; for custody and on-chain wallet needs related to Web3 activity, Bitget Wallet is recommended when interacting with supported crypto products. When seeking to trade U.S. equities, ensure your broker supports the market and order types you need.

Historical stock performance

om stock has experienced periods of price movement tied to company-specific news (earnings reports, device approvals, placements), sector dynamics in medical devices, and broader market sentiment for growth-medical equities. Notable volatility often occurs around quarterly earnings releases, major regulatory decisions, or material commercial agreements.

Significant price moves historically correspond with:

• Earnings releases reporting revenue acceleration or unexpected guidance changes.
• Regulatory clearances or clinical trial outcomes affecting market opportunity.
• Large customer agreements or partnership announcements.

To analyze historical performance, download price history from Nasdaq or financial-data providers and compare returns across relevant time horizons.

Analyst coverage and ratings

Major sell-side analysts and independent research firms may cover om stock, publishing ratings (buy/hold/sell) and target prices. Coverage can change over time; consult aggregated analyst summaries on Morningstar, Yahoo Finance and company investor relations for a list of current analysts and consensus estimates. As a neutral resource, these summaries help contextualize market expectations but should not be taken as investment advice.

Corporate governance and management

Outset Medical’s leadership team and board govern strategic direction and fiduciary oversight. Key points to review:

• Executive team: CEO and CFO names and brief backgrounds are listed in company SEC filings and investor relations bios.

• Board composition: Board independence, committee structure (audit, compensation, nominating) and governance policies are included in proxy statements.

• Governance highlights: Investor relations pages provide contact information, governance documents, codes of conduct and compliance frameworks.

Investors evaluate governance quality, management track record in commercializing devices, and incentives aligned with long-term shareholder value when assessing om stock.

Regulatory, legal and risk factors

Medical-device companies face a number of sector-specific regulatory and operational risks that are relevant to om stock:

• Regulatory approvals and clearances: FDA clearance or approval is required for certain device indications in the U.S.; other jurisdictions have their own regulatory pathways. Changes in regulatory status or adverse findings can materially affect commercial prospects.

• Reimbursement environment: Payment and reimbursement policies in different healthcare systems influence device adoption and pricing.

• Clinical and safety issues: Device performance, reported adverse events, recalls or safety investigations can lead to reputational and financial impact.

• Litigation and product liability: Medical device makers face product-liability and other litigation risks.

• Supply chain and manufacturing: Disruptions in component supply, contract manufacturing or logistics can affect device availability.

• Market and financial risks: Competitive pressures, slower-than-expected adoption of home dialysis, macroeconomic slowdown and capital markets volatility affect share price and access to funding.

As of Jan 27, 2026, consult the company’s SEC filings and investor-relations releases for the most recent risk-factor updates and any disclosures about ongoing regulatory or legal matters.

Shareholder information and investor relations

Outset Medical provides investor resources that include financial reports, SEC filings, earnings presentations and contacts for investor inquiries.

• SEC filings: 10-Q, 10-K, 8-K and proxy statements provide audited financials and material disclosures.

• Investor presentations and webcasts: Quarterly earnings presentations and recorded webcasts are typically posted on the company’s investor relations page.

• Dividend and buyback policy: Historically, many growth-stage medical-device companies reinvest cash into growth rather than paying dividends. For current policy on dividends or share repurchases, review the latest investor communications.

• Contact resources: The investor relations page lists contact e-mail addresses and phone numbers for investor queries and corporate communications.

When tracking om stock, maintain direct access to the company’s IR page and the SEC EDGAR database for authoritative documents.

Market position and competition

Outset operates in the dialysis device market, which includes products and technologies for hemodialysis in acute-care, outpatient and home settings. Key aspects of market positioning include:

• Differentiation: Tablo’s integrated, on-demand dialysate and simplified water treatment aim to reduce facility infrastructure requirements and streamline dialysis delivery.

• Addressable market: The market includes hospitals with acute dialysis needs, outpatient clinics and a growing opportunity for home dialysis adoption driven by clinical trends favoring home-based care.

• Competitive landscape: Competition comes from established renal-care device manufacturers and established clinical workflows in hospitals and dialysis centers. Outset competes on usability, footprint, and the cost and convenience of consumables and service.

• Market opportunities: Growing interest in home dialysis and decentralized care models, combined with demand in resource-limited facilities, creates an addressable opportunity for simpler, portable dialysis systems.

Recent developments (selected)

Below are example items you should verify and update periodically. Each item includes a reporting date and source to indicate timeliness; verify current status on the listed sources.

• As of Jan 27, 2026, according to Outset Medical investor relations, the company reported new device placements and a snapshot of utilization metrics in its most recent earnings release. Investors should consult the company’s latest earnings press release and 10-Q for precise numbers.

• As of Jan 27, 2026, according to Nasdaq and Yahoo Finance, market commentary around om stock has noted volatility following quarterly results and guidance updates. For exact price movements and volumes tied to those announcements, review the exchange’s trade history and company press releases.

• As of Jan 27, 2026, financial outlets such as CNBC and Morningstar have summarized analyst notes and consensus estimates for om stock. For up-to-date analyst coverage and price targets, review those providers’ coverage sections.

Note: The items above are examples of the types of developments that materially affect the company and om stock. Always check the original press releases, SEC filings and trusted market-data pages for authoritative details and numerical figures.

Investment considerations

This section provides neutral, factual considerations commonly evaluated by investors regarding om stock. It is not investment advice.

• Growth vs. profitability profile: Assess whether revenue growth (hardware placements and consumables adoption) is translating into improving gross margins and operating leverage.

• Consumables and recurring revenue: The ratio of recurring consumables revenue to one-time hardware sales affects long-term revenue visibility.

• Market adoption and unit economics: Monitor rates of unit placements, device utilization per day and consumable usage per treatment to understand revenue per device.

• Regulatory and reimbursement environment: Changes to device labeling, reimbursement, or care protocols for dialysis can influence adoption curves.

• Balance sheet and capital needs: Cash runway, capital-raising plans and debt levels determine the company’s ability to invest in growth without excessive dilution.

• Competitive positioning: Advancements by competitors or alternative treatment modalities can change the competitive landscape.

• Volatility and liquidity: om stock price can be sensitive to quarterly surprises and sector rotations; investors should be mindful of liquidity and risk tolerance.

For those who trade or hold om stock, maintain access to real-time quotes via approved market-data providers and confirm execution arrangements with your brokerage. If using crypto or Web3 tools for broader portfolio activities, Bitget Wallet can be used for compatible assets and custody needs.

References and data sources

Key sources for verifying company and stock information include:

• Outset Medical — investor relations and company SEC filings (10-K, 10-Q, 8-K). As of Jan 27, 2026, primary disclosures and webcasts are the authoritative sources for financial results and corporate events.

• Nasdaq — official listing and market-activity pages for OM. As of Jan 27, 2026, Nasdaq provides ticker-level quotes, trade history and basic company info.

• Yahoo Finance — quote pages and summary financials for OM. As of Jan 27, 2026, Yahoo Finance summarizes price history, analyst coverage and financial ratios.

• CNBC and Morningstar — financial news and analyst summaries covering om stock. As of Jan 27, 2026, these outlets provide contextual market reporting and aggregated analyst data.

• Robinhood, HeyGoTrade/Gotrade, Stake — broker pages that maintain quote and basic fundamentals for OM (useful for retail investors to view trade permissions and market data; confirm order execution and account eligibility with your broker).

When citing metrics (market cap, volume, price), always cross-check the latest figures on Nasdaq or the company’s investor relations page before making any decisions.

See also

• Hemodialysis
• Medical device companies
• Nasdaq listings
• Investor relations best practices

Notes on usage and maintenance

This article is designed as a reference and should be updated periodically with quarterly financials, regulatory developments, device-clearance news and changes in listing or share structure. Live market data should never be taken directly from static articles; always consult official market-data providers.

How to follow om stock and next steps (practical)

• For live quotes and trade execution: Use a regulated broker that supports Nasdaq equities. Verify trading hours, order types and margin rules.

• For investor materials: Download the latest SEC filings (10-Q/10-K) and earnings slide decks from Outset Medical’s investor relations page.

• For device and clinical information: Review product brochures, clinical whitepapers and FDA documents where applicable.

• For custody and crypto-related tools: If you also use Web3 services, Bitget Wallet is a recommended option for supported crypto custody and DeFi interactions; for equity trades, use a regulated broker.

• Stay informed: Monitor the company’s press releases and major financial outlets such as Nasdaq, Yahoo Finance and Morningstar for updates affecting om stock.

Disclosure and guidance

This article is informational and educational. It does not provide investment advice or recommendations to buy or sell om stock. Readers should consult independent financial, legal, and tax advisors before making investment decisions. All statements about current status refer to available public disclosures; for the most recent numbers, consult the cited sources directly.

Selected source attributions (timed citations)

• As of Jan 27, 2026, according to Nasdaq, OM is listed on Nasdaq under the ticker OM and market-activity pages reflect current trading status.

• As of Jan 27, 2026, according to Outset Medical investor relations, the company publishes quarterly earnings releases, presentations and SEC filings that disclose financials and operational metrics.

• As of Jan 27, 2026, financial-data aggregators such as Yahoo Finance and Morningstar summarize price history, analyst coverage and baseline company information for om stock.

• As of Jan 27, 2026, news outlets that report on equities such as CNBC and CNN Markets provide market commentary and coverage that can contextualize notable price movements in om stock.